Global /Taiwan /Healthcare /Medical Care Facilities /6615
chevron_leftBack
Sofiva Genomics Co.,Ltd. logo

Sofiva Genomics Co.,Ltd.

6615
TPEX: 6615 Delayed
33.45TWD 1.1%
1.06 USD
As of 5 June 2026, Sofiva Genomics Co.,Ltd. has a market cap of $22.71M USD, ranking #36227 globally and #2208 in Taiwan. It ranks #3253 in the Healthcare sector, and #397 in the Medical Care Facilities industry.
Global Rank
36227
Country Rank
2208
Sector Rank
3253
Industry Rank
397
Key Stats
Market Cap
$22.71MUSD
714.74M TWD
Enterprise Value
$19.9MUSD
625.87M TWD
Revenue (TTM)
$12.26MUSD
385.71M TWD
EBITDA (TTM)
-$225.2KUSD
-7.08M TWD
Net Income (TTM)
-$297.42KUSD
-9.36M TWD
EBITDA Margin
-1.8%
Profit Margin
-2.4%
PS Ratio
1.9
PB Ratio
1.1
EV/EBITDA
20.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Chia-Cheng Hung open_in_new
Employees
104
Founded
2012
Website
sofivagenomics.com.tw open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.1% -1.6% -4.1% 12% 4.9% -6.1%

News

Loading...

Markets

Exchange Ticker Price
Taipei Exchange
MIC: ROCO
PRIMARY
6615
慧智基因股份有限公司
ISIN: TW0006615008
Shares Out.:
21.593M1
TV:
SA:
YF:
GF:
BA:
MS:
33.45 TWD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Sofiva Genomics Co.,Ltd.

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). In addition, the company offers cancer screening services, which includes human papillomavirus screening (HPV); and hereditary cancer testing services. Further, it develops precision medicine genetic testing; and offers testing services to patients and carriers with rare disorders. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.

Similar Companies

Industry: Medical Care Facilities (Taiwan)
Name
Market Cap diff.
PE
$374.22M
11.78B TWD
2K%
11.3
$101.63M
3.2B TWD
347%
34.8
7803
$87.53M
2.75B TWD
285%
-
$65.97M
2.08B TWD
190%
-
$41.93M
1.32B TWD
85%
-
$37.06M
1.17B TWD
63%
54.6
Industry: Medical Care Facilities (Global)
Name
Market Cap diff.
PE
$232.22B
852.82B AED
1M%
44.1
$96.73B
426K%
14.9
$26.65B
22.97B EUR
117K%
15.0
$25.54B
22.02B EUR
112K%
24.9
$22.47B
84.42B SAR
99K%
35.2
$21.13B
93K%
24.6
chevron_leftBack